How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
GMP Grade Peptide Market
- By Peptide Type: Linear Peptides, Cyclic Peptides, Modified Peptides, Peptidomimetics, Conjugated Peptides
- By Application: Pharmaceuticals, Biotechnology Research, Diagnostic Agents, Cosmeceuticals, Vaccine Development
- By Synthesis Method: Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Recombinant Peptide Production
- By Purity Grade: ≥95% Purity, ≥98% Purity, ≥99% Purity
- By End-Use Industry: Pharmaceutical Companies, Contract Research Organizations (CROs), Academic and Research Institutes, Biotech Startups
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Linear Peptides leads By Peptide Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.178 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.186 →
Full report · locked preview
Everything inside the GMP Grade Peptide Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Peptide Type 5
Application 5
Synthesis Method 3
Purity Grade 3
End-Use Industry 4
Companies profiled
Lonza Group AG
Bachem Holding AG
CordenPharma International GmbH
Polypeptide Group
Siegfried Holding AG
PeptiDream Inc.
AmbioPharm Inc.
CPC Scientific Inc.
GenScript Biotech Corporation
Thermo Fisher Scientific Inc.
Sino Biological Inc.
Shanghai Hanhong Scientific Co. Ltd.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Lonza Group AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bachem Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →CordenPharma International GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Polypeptide Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Siegfried Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →PeptiDream Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →AmbioPharm Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →CPC Scientific Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →GenScript Biotech Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Thermo Fisher Scientific Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sino Biological Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Shanghai Hanhong Scientific Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →JPT Peptide Technologies GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →ChinaPeptides Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →CSBio Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,619M by 2033 · 4.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Linear Peptides43.4
- Cyclic Peptides10.1
- Modified Peptides22.0
- Peptidomimetics14.2
- Conjugated Peptides10.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$845.8M → $1,183M · 4.3%
Europe$589.5M → $859.6M · 4.8%
Asia Pacific$538.2M → $769.1M · 4.6%
Latin America$333.2M → $466.5M · 4.3%
Middle East and Africa$256.3M → $408.0M · 6.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.352026
4.382027
4.382028
4.402029
4.412030
4.412031
4.442032
4.432033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Lonza Group AG12.5
- Bachem Holding AG29.5
- CordenPharma International GmbH9.3
- Polypeptide Group8.4
- Siegfried Holding AG6.2
- PeptiDream Inc.6.1
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Peptide Type22.9%
Application12.2%
Synthesis Method28.6%
Purity Grade24.6%
End-Use Industry11.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.1
- Europe23.3
- Asia Pacific20.9
- Latin America12.7
- Middle East and Africa11.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Lonza Group AG | 85 | 87 | 92 | 85 | 94 | 92 | 89 |
| Bachem Holding AG | 82 | 87 | 82 | 92 | 86 | 68 | 83 |
| CordenPharma International GmbH | 64 | 67 | 69 | 79 | 81 | 88 | 75 |
| Polypeptide Group | 58 | 60 | 78 | 61 | 64 | 76 | 66 |
| Siegfried Holding AG | 68 | 72 | 56 | 77 | 61 | 74 | 68 |
| PeptiDream Inc. | 48 | 49 | 59 | 70 | 50 | 52 | 55 |
| AmbioPharm Inc. | 62 | 45 | 45 | 51 | 57 | 66 | 54 |
| CPC Scientific Inc. | 52 | 59 | 36 | 45 | 59 | 38 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Lonza Group AG
- Bachem Holding AG
- CordenPharma International GmbH
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Lonza Group AG | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Bachem Holding AG | ✓ | ✓ | ◐ | ✓ | ✓ | − |
| CordenPharma International GmbH | ◐ | − | − | ✓ | ◐ | ✓ |
| Polypeptide Group | − | ◐ | ✓ | ◐ | − | ✓ |
| Siegfried Holding AG | ◐ | ✓ | − | ◐ | ◐ | ◐ |
| PeptiDream Inc. | − | − | ◐ | ◐ | − | − |
| AmbioPharm Inc. | ◐ | − | − | ◐ | − | ◐ |
| CPC Scientific Inc. | − | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Lonza Group AG89
2Bachem Holding AG83
3CordenPharma International GmbH75
4Siegfried Holding AG68
5Polypeptide Group66
6PeptiDream Inc.55
7AmbioPharm Inc.54
8CPC Scientific Inc.48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Lonza Group AGBachem Holding AG
Challenger2
Strong scale, closing on the leaders.
CordenPharma International GmbHSiegfried Holding AG
Contender1
Focused players with pockets of strength.
Polypeptide Group
Niche3
Specialists in a single segment or region.
PeptiDream Inc.AmbioPharm Inc.CPC Scientific Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Peptide Type in North America, then scale across GMP Grade Peptide Market — a $526M beachhead inside a $7.13B market.
Beachhead (SOM)$526Mobtainable near-term
Serviceable (SAM)$2.89Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Linear Peptides
Best fit — highest urgency & budget in Peptide Type.
Economic buyer76 fit
Cyclic Peptides
Strong fit — clear ROI and a fast path to value.
End user65 fit
Modified Peptides
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Peptide Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Synthesis Method
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Peptide Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win GMP Grade Peptide Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified25%
Evaluation14%
Closed-won6%
$11.9KCAC
$41KLTV
3.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
GMP Grade Peptide Market is a high-growth opportunity — $9.85B by 2033, compounding at 11.0%.
TAM · 2025$4.28Btoday
TAM · 2033$9.85Bforecast
CAGR11.0%2027–2033
Cumulative$60.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.85BTotal addressable market
SAM$3.49BServiceable available market
SOM$629MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.0% CAGR
Demand compounds through 2033, outpacing GDP across Peptide Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Peptide Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.85BLarge & growingTAM by 2033 at 11.0% CAGR
$3.49BServiceable nowreachable with today’s model
$629MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.68BBear7.1% CAGR
$9.85BBase11.0% CAGR
$12.6BBull14.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
GMP Grade Peptide Market — a $1.29B market by 2033. Plan: grow share from 11.0% to 18.0%.
Market size · 2033$1.29Btotal addressable
Market CAGR4.2%2027–2033
Target share18.0%from 11.0% today
Revenue ambition$231Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.0% | 18.0% | Ahead |
| Revenue | $137M | $231M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 29.3% | 40.3% | On track |
| Customer retention | 88.6% | 92.7% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Peptide Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Peptide Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $24M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Peptide Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the GMP Grade Peptide Market conversation — a $840M market you can size, segment and defend in minutes.
Market size · 2033$840Mtotal opportunity
Growth3.5%CAGR to 2033
Addressable buyers979+accounts in scope
Typical ROI4.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Peptide Type
Goal Grow share in Peptide Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.7×return on cost, year one
< 4 mopayback period
$90K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Lonza Group AGBachem Holding AGCordenPharma International GmbHPolypeptide GroupSiegfried Holding AGPeptiDream Inc.AmbioPharm Inc.CPC Scientific Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your GMP Grade Peptide Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
GMP Grade Peptide Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →GMP-grade Mesenchymal Stem Cell Media Market
Market size, share, segmentation and regional forecast.
$561M market · 2025 base year
View reportGMP Grade Fetal Bovine Serum Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportGMP Grade Cryopreservation Medium Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportLaboratory Gas Generator Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportGMP Grade Cell Freezing Media Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportGMP Cabinet Washer Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportGMP Analytical Services Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportGMO Detection Kit Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportGM1 Gangliosidosis Treatment Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportPortable Oxygen Generator Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportGly-His-Lys Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportGlycyrrhizine Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.